Intravesical Biologic Formulation for Bladder Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical administration methods for treating bladder disorders, such as overactive bladder, via botulinum toxin injections are invasive and can cause pain, and the bladder wall's impermeability hinders effective drug delivery, necessitating a method to enhance permeability without causing damage.
Innovation Solution
A pharmaceutical formulation comprising a clostridial derivative, specifically a botulinum toxin, combined with a non-ionic surfactant and a cationic mucoadhesive polymer, such as chitosan, to increase the bladder wall's permeability for therapeutic delivery through intravesical instillation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If parenteral injection is used to deliver botulinum toxin to the bladder, then the drug can reach the target tissue, but the procedure causes localized pain and exposes patients to blood borne diseases
Solution Approach 1:
The patent uses the urinary bladder lumen as an intermediary pathway to deliver botulinum toxin directly to the detrusor muscle, avoiding parenteral injection. The toxin is instilled into the bladder and transported across the urothelium to reach the target tissue, thereby eliminating pain and infection risks associated with needle injection while maintaining therapeutic effectiveness
Solution Approach 2:
The patent replaces the mechanical injection system (needles, syringes) with a chemical delivery system using permeabilizing agents. These agents chemically modify the urothelium to increase permeability, allowing the toxin to passively or actively traverse the barrier without mechanical penetration, thus eliminating pain and tissue trauma
2Object-affected harmful factors
If intravesical instillation is used to avoid injection pain, then the drug can be delivered non-invasively, but the bladder wall's impermeability prevents effective drug delivery
Solution Approach 1:
The patent applies permeabilizing agents that chemically modify the urothelium's permeability parameters. These agents temporarily alter the physical and chemical properties of the bladder wall, increasing its permeability to botulinum toxin while maintaining reversibility, thus enabling effective drug delivery without compromising the protective barrier function
Solution Approach 2:
The patent employs composite formulations combining botulinum toxin with permeabilizing agents and mucoadhesive polymers. This composite approach allows the formulation to simultaneously achieve barrier penetration, prolonged residence time in the bladder, and effective toxin delivery to the detrusor muscle, overcoming the impermeability issue
3Reliability
If the bladder wall permeability is increased to allow drug passage, then intravesical delivery becomes effective, but the bladder wall integrity may be compromised
Solution Approach 1:
The patent incorporates mucoadhesive polymers in the formulation that provide protective cushioning to the urothelium during the permeabilization process. These polymers form a protective layer that mitigates potential damage from permeabilizing agents while facilitating toxin transport, thus preserving bladder wall integrity during enhanced permeability
Solution Approach 2:
The patent creates a dynamic, reversible permeability enhancement system. The permeabilizing agents temporarily increase bladder wall permeability during the instillation period, then naturally revert to baseline permeability, allowing the bladder wall to maintain its protective function while enabling effective drug delivery during the treatment window
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively increases bladder wall permeability, allowing a therapeutically effective amount of the botulinum toxin to reach the target area, reducing symptoms of bladder disorders like overactive bladder and neurogenic bladder dysfunction without causing irreversible damage to the bladder.
Implementation Method 1
the at least one permeabilizing agent is present in an amount effective to substantially and reversibly increase the permeability of the bladder wall to the clostridial derivative
Implementation Method 2
the at least one permeabilizing agent comprises a non-ionic surfactant and a mucoadhesive, which is a cationic polymer
Data Source
Figure 1
Figure 2A~2C
Figure 3
AI summary
Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.